Medacta Forecast, price target & analysts
Medacta Target price 2025 - Analyst rating & recommendation
Medacta Classifications & Recommendation:
Medacta Price Target
| Target Price | CHF160.14 |
| Price | CHF150.80 |
| Potential |
6.19%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Medacta 2026 .
The average Medacta target price is CHF160.14.
This is
6.19%
register free of charge
CHF183.75
21.85%
register free of charge
CHF152.51
1.13%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Medacta to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medacta stock has an average upside potential 2026 of
6.19%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 544.89 | 648.81 |
| 15.62% | 18.90% | |
| EBITDA Margin | 19.30% | 26.92% |
| 4.21% | 39.47% | |
| Net Margin | 12.34% | 12.93% |
| 33.10% | 4.77% |
8 Analysts have issued a sales forecast Medacta 2025 . The average Medacta sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Medacta EBITDA forecast 2025. The average Medacta EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Medacta Analysts have issued a net profit forecast 2025. The average Medacta net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 3.37 | 4.21 |
| 53.88% | 24.93% | |
| P/E | 36.14 | |
| EV/Sales | 5.04 |
8 Analysts have issued a Medacta forecast for earnings per share. The average Medacta EPS is
This results in the following potential growth metrics and future valuations:
Current Medacta Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 02 2025 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 02 2025 |
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| STIFEL, FORMERLY BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 02 2025 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 01 2025 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 02 2025 |
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
STIFEL, FORMERLY BRYAN GARNIER:
Locked
➜
Locked
|
Apr 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
